Assessment of the effectiveness and safety of bevacizumab-based therapies for recurrent primary brain tumors: a multicenter real-world study by the Turkish Oncology Group (TOG) - Scorecard - MDSpire
Advertisement
Assessment of the effectiveness and safety of bevacizumab-based therapies for recurrent primary brain tumors: a multicenter real-world study by the Turkish Oncology Group (TOG)
Clinical Scorecard: Assessment of the effectiveness and safety of bevacizumab-based therapies for recurrent primary brain tumors: a multicenter real-world study by the Turkish Oncology Group (TOG)
At a Glance
Category
Detail
Condition
Recurrent primary brain tumors, including glioblastoma, anaplastic astrocytoma, and oligodendroglioma
Key Mechanisms
Bevacizumab targets VEGF to inhibit angiogenesis, a key driver in high-grade gliomas; irinotecan, a topoisomerase I inhibitor, penetrates the blood-brain barrier and may enhance disease control
Target Population
Adults (≥18 years) with recurrent primary brain malignancies, ECOG performance status 0–2, treated at first or second recurrence
Care Setting
Multicenter oncology centers in Turkey, real-world clinical practice
Key Highlights
Bevacizumab-based regimens, alone or combined with irinotecan, improve progression-free survival and radiographic response rates but have not demonstrated overall survival benefit in phase III trials.
Combination of bevacizumab with irinotecan may enhance disease control compared to bevacizumab monotherapy, though survival outcomes remain similar.
Real-world data on bevacizumab-based therapies for recurrent brain tumors are limited; this study provides multicenter retrospective insights into effectiveness and safety.
Guideline-Based Recommendations
Diagnosis
Histological confirmation of glioblastoma, anaplastic astrocytoma, or oligodendroglioma via surgical resection or biopsy.
Radiological assessment of tumor response using McDonald criteria in routine clinical practice.
Management
Consider bevacizumab monotherapy or in combination with irinotecan for recurrent primary brain tumors, especially at first or second recurrence.
Dose irinotecan based on enzyme-inducing antiepileptic drug use: low-dose weekly or standard-dose regimens combined with bevacizumab 10 mg/kg every 14 days.
Treatment selection should consider patient performance status, tolerability, and institutional protocols.
Monitoring & Follow-up
Radiological evaluation every eight weeks to assess tumor response.
Systematic recording of treatment-related adverse events including gastrointestinal, hematologic, hemorrhage, thrombosis, hypertension, and proteinuria.
Monitor ECOG performance status and clinical symptoms regularly.
Risks
Potential bevacizumab-associated toxicities such as hemorrhage, thrombosis, hypertension, and proteinuria.
Adverse events related to irinotecan including gastrointestinal and hematologic toxicities.
Exclusion of patients with uncontrolled cardiovascular disease or significant organ dysfunction due to increased risk.
Patient & Prescribing Data
Adults with recurrent glioblastoma, anaplastic astrocytoma, or oligodendroglioma, ECOG PS 0–2, treated at first or second recurrence in real-world Turkish oncology centers.
Bevacizumab administered at 10 mg/kg every 14 days, alone or combined with irinotecan dosed according to antiepileptic drug use, shows improved progression-free survival and response rates but no clear overall survival benefit; safety profile consistent with known toxicities.
Clinical Best Practices
Select patients with good performance status (ECOG 0–2) and no significant comorbidities for bevacizumab-based therapy.
Adjust irinotecan dosing based on concomitant enzyme-inducing antiepileptic drugs to optimize efficacy and minimize toxicity.
Perform regular imaging every 8 weeks and monitor for adverse events to guide treatment continuation or modification.
Avoid bevacizumab in patients with recent stroke, uncontrolled cardiovascular disease, or significant hepatic, renal, or hematologic dysfunction.
he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.
